A
ACTUATE THERAPEUTICS, INC.
Period
FY 2025
Revenue
—
Net Income
$-22.23M
Total Assets
$14.04M
Equity
$7.92M
Shares Out
23.93M
Op. Cash Flow
$-19.21M
Business
Actuate Therapeutics is a clinical-stage biopharmaceutical company developing elraglusib, a GSK-3β inhibitor small molecule for treating high-impact, difficult-to-treat cancers. The company's lead program evaluates Elraglusib Injection in combination with standard chemotherapy for metastatic pancreatic ductal adenocarcinoma, with Phase 2 data showing statistically significant survival benefit; it also develops Elraglusib Oral Tablet and supports investigator-initiated trials in pediatric cancers including Ewing sarcoma and neuroblastoma. The company operates through licensed technology from Northwestern University and the University of Illinois-Chicago, with research partnerships including Lantern Pharma for biomarker development.
Summary from 10-K filed 2026-03-26
Financials
Consolidated Statement of Income
Year Ended · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 |
|---|---|---|---|---|
| Research and development | 10 | 19 | 22 | |
| General and administrative | 12 | 6 | 3 | |
| Total operating expenses | 22 | 25 | 25 | |
| Loss from operations | −22 | −25 | −25 | |
| Change in estimated fair value of warrant liability | 0 | −78,903 | −79,822 | |
| Gain on settlement of warrants | 0 | 343,240 | 0 | |
| Loss on issuance of related party convertible notes payable at fair value | 0 | −400,000 | 0 | |
| Change in estimated fair value of related party convertible notes payable | 0 | −2 | 0 | |
| Interest expense | −20,250 | −18,717 | −43,641 | |
| Interest income | 287,710 | 222,293 | 352,672 | |
| Total other income (expense), net | 267,460 | −2 | 229,209 | |
| Net loss | −22 | −27 | −25 | |
| Weighted-average shares of common stock outstanding, basic | 21 | 8 | 1 | |
| Weighted-average shares of common stock outstanding, diluted | 21 | 8 | 1 | |
| Net loss per share attributable to common stockholders, basic | −1.06 | −3.26 | −17.24 | |
| Net loss per share attributable to common stockholders, diluted | −1.06 | −3.26 | −17.24 |
Consolidated Balance Sheet
As of · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 |
|---|---|---|---|---|---|
| Cash and cash equivalents | 13 | 9 | 3 | — | |
| Prepaid assets and other current assets | 483,996 | 566,278 | 36,907 | — | |
| Total current assets | 14 | 9 | 3 | — | |
| Deferred offering costs and other assets | 392,491 | 110,548 | 0 | — | |
| Total assets | 14 | 9 | 3 | — | |
| Accounts payable | 2 | 2 | 3 | — | |
| Other accrued expenses | 4 | 6 | 3 | — | |
| Accrued compensation | 588,304 | 888,449 | 277,500 | — | |
| Accrued interest, current | 27,018 | 70,957 | 0 | — | |
| Total current liabilities | 6 | 9 | 7 | — | |
| Accrued interest, less current portion | 0 | 6,768 | — | — | |
| License payable | 404,991 | 404,991 | — | — | |
| Total long-term liabilities | 404,991 | 411,759 | 2 | — | |
| Total liabilities | 6 | 9 | 8 | — | |
| Commitments and contingencies (Note 6) | — | — | — | — | |
| Preferred stock, $0.000001 par value, 10,000,000 shares authorized, no shares issued or outstanding | 0 | 0 | 0 | — | |
| Common stock, $0.000001 par value, 200,000,000 shares authorized, 23,245,203 and 19,531,636 shares issued and outstanding at December 31, 2025 and 2024, respectively | 23 | 20 | 2 | — | |
| Additional paid-in capital | 163 | 132 | 5 | — | |
| Accumulated deficit | −155 | −132 | −105 | — | |
| Total stockholders equity | 8 | 104,186 | −100 | −75 | |
| Total liabilities and stockholders equity | 14 | 9 | 3 | — |
Consolidated Statement of Cash Flows
Year Ended · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 |
|---|---|---|---|---|
| Stock-based compensation expense | 6 | 2 | 423,539 | |
| Gain on settlement of warrant liability | 0 | −343,240 | 0 | |
| Loss on issuance of related party convertible notes payable at fair value | 0 | 400,000 | 0 | |
| Change in estimated fair value of related party convertible notes payable | 0 | 2 | 0 | |
| Interest accrued on license payable | 20,250 | 18,641 | — | |
| Prepaid assets and other current assets | 82,282 | −529,371 | −3,161 | |
| Other assets | 110,548 | −110,548 | 0 | |
| Accounts payable | −512,536 | −2 | 1 | |
| Accrued compensation | −300,145 | 610,949 | 145,467 | |
| Accrued interest | −70,957 | −70,957 | 0 | |
| Other accrued expenses | −2 | 3 | 1 | |
| Net cash used in operating activities | −19 | −22 | −22 | |
| Proceeds from issuance of shares of common stock under underwritten public offering, net of underwriting discounts and offering costs | 16 | 0 | — | |
| Proceeds from issuance of shares of common stock under June 2025 Private Placement, net | 5 | 0 | — | |
| Proceeds from issuance of shares of common stock under the Committed Equity Facility, net | 4 | 0 | — | |
| Proceeds from the exercise of stock options | 34,115 | 0 | — | |
| Proceeds from initial public offering, net of underwriting discounts and commissions | 0 | 24 | 0 | |
| Payment of offering costs related to initial public offering | 0 | −2 | 0 | |
| Proceeds from issuance of related party short-term loan | 0 | 200,000 | 0 | |
| Payment of related party short-term loan | 0 | −200,000 | 0 | |
| Proceeds from issuances of related party convertible notes payable | 0 | 6 | 0 | |
| Net cash provided by financing activities | 24 | 28 | 4 | |
| Net change in cash and cash equivalents | 5 | 6 | −17 | |
| Cash paid for interest | 70,957 | 71,033 | 0 | |
| Cash paid for income taxes | 800 | 800 | 0 | |
| Conversion of redeemable convertible preferred stock into common stock upon initial public offering | 0 | 94 | 0 | |
| Reclassification of warrant liability to equity upon exchange of not in-the-money Series B and Series C Redeemable Convertible Preferred Stock Warrants for warrants to purchase common stock | 0 | 485,172 | 0 | |
| Exercise of in-the-money warrants to purchase redeemable convertible preferred stock and conversion into common stock upon initial public offering | 0 | 238,540 | 0 | |
| Conversion of related party convertible notes payable into common stock upon initial public offering | 0 | 8 | 0 | |
| Deferred offering costs, unpaid and accrued | 115,537 | 0 | — | |
| Deferred offering costs charged against Committed Equity Facility | 25,871 | 0 | — |
Filings
Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro
Material Events
Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro
Insiders
Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro
Institutional Holders
Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro
Frequently asked questions
What is ACTUATE THERAPEUTICS, INC.'s CIK number?
ACTUATE THERAPEUTICS, INC.'s SEC CIK number is 0001652935 (1652935). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find ACTUATE THERAPEUTICS, INC.'s SEC filings?
All of ACTUATE THERAPEUTICS, INC.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.